Benjamin Burnett analyst WELLS FARGO

Currently out of the existing stock ratings of Benjamin Burnett, 200 are a BUY (72.2%), 77 are a HOLD (27.8%).

Benjamin Burnett

Work Performance Price Targets & Ratings Chart

Analyst Benjamin Burnett, currently employed at WELLS FARGO, carries an average stock price target met ratio of 46.33% that have a potential upside of 35.86% achieved within 129 days. Previously, Benjamin Burnett worked at STIFEL.

Benjamin Burnett’s has documented 523 price targets and ratings displayed on 44 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ALKS, Alkermes Plc at 29-Jun-2026.

Wall Street Analyst Benjamin Burnett

Analyst best performing recommendations are on EFTR (EFFECTOR THERAPEUTICS).
The best stock recommendation documented was for CRSP (CRISPR THERAPEUTICS AG) at 2/13/2025. The price target of $49 was fulfilled within 1 day with a profit of $5.51 (12.67%) receiving and performance score of 126.7.

Average potential price target upside

ALLO Allogene Therapeutics ATRA Atara Biotherapeutics BLUE Bluebird bio CRSP Crispr Therapeutics AG CTIC CTi Biopharma Corp DTIL Precision BioSciences FATE Fate Therapeutics GBT Global Blood Therapeutics IOVA Iovance Biotherapeutics MRTX Mirati Ther NKTR Nektar Therapeutics SGMO Sangamo Therapeutics PGEN Precigen IDYA Ideaya Biosciences RPTX Repare Therapeutics RVMD Revolution Medicines EFTR Effector Therapeutics GNCA Genocea Biosciences NLTX Neoleukin Therapeutics BEAM Beam Therapeutics  KNTE Kinnate Biopharma  ACLX Arcellx GRCL Gracell Biotechnologies IRON Disc Medicine ALKS Alkermes Plc AVDL Avadel Pharmaceuticals PLC AXSM Axsome Therapeutics CNTA Centessa Pharmaceuticals PLC ADR XENE Xenon Pharmaceuticals WVE Wave Life Sciences Ltd UTHR United Therapeutics INSM Insmed BL Blackline GBTG Global Business Travel Group KN Knowles Cor KROS Keros Therapeutics  LQDA Liquidia Technologies MNKD MannKind Corp PRAX Praxis Precision Medicines  PTCT PTC Therapeutics RPT RPT Realty CABA Cabaletta Bio RARE Ultragenyx SVRA Savara

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 04-Apr-2023

$11

$8.87 (416.43%)

$12

2 months 22 days ago
(16-Apr-2026)

0/12 (0%)

$8.63 (364.14%)

Hold Since 21-Mar-2023

$3.85

$1.72 (80.75%)

$2.5

2 months 24 days ago
(14-Apr-2026)

2/3 (66.67%)

$1.13 (41.54%)

155

Buy Since 14-May-2025

$9

$6.87 (322.54%)

$9

2 months 24 days ago
(14-Apr-2026)

1/4 (25%)

$6.28 (230.88%)

19

Buy Since 05-Nov-2018

$8

$5.87 (275.59%)

3 months 25 days ago
(13-Mar-2026)

2/7 (28.57%)

$5.6 (233.33%)

3

Buy Since 04-Nov-2019

3 months 25 days ago
(13-Mar-2026)

1/2 (50%)

$28.66 (452.05%)

192

Show more analysts

Please expand the browser size to see the chart

Which stock is Benjamin Burnett is most bullish on?

Potential upside of $182.09 has been obtained for UTHR (UNITED THERAPEUTICS)

Which stock is Benjamin Burnett is most reserved on?

Potential downside of -$16.93 has been obtained for LQDA (LIQUIDIA TECHNOLOGIES)

What Year was the first public recommendation made by Benjamin Burnett?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?